These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34195237)

  • 21. Blood pressure visit-to-visit variability and outcomes in patients with heart failure with preserved ejection fraction.
    Zhang Q; Zhou B; Ma Y; Hu Y; Li X; Cong H
    ESC Heart Fail; 2021 Oct; 8(5):3984-3996. PubMed ID: 34405581
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Importance of Temporal Changes in Resting Heart Rate in Heart Failure and Preserved Ejection Fraction: From the TOPCAT Study.
    Vazir A; Claggett B; Pitt B; Anand I; Sweitzer N; Fang J; Fleg J; Rouleau J; Shah S; Pfeffer MA; Solomon SD
    JACC Heart Fail; 2017 Nov; 5(11):782-791. PubMed ID: 29032132
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral artery disease and risk of adverse outcomes in heart failure with preserved ejection fraction.
    Sandesara PB; Hammadah M; Samman-Tahhan A; Kelli HM; O'Neal WT
    Clin Cardiol; 2017 Sep; 40(9):692-696. PubMed ID: 28444995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction.
    Selvaraj S; Claggett B; Shah SJ; Anand I; Rouleau JL; O'Meara E; Desai AS; Lewis EF; Pitt B; Sweitzer NK; Fang JC; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2018 Nov; 11(11):e005288. PubMed ID: 30571191
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CHA2DS2-VASc and ATRIA Scores and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Zhu W; Wu Y; Zhou Y; Liang W; Xue R; Wu Z; Dong Y; Liu C
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):763-772. PubMed ID: 32583288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prior Pacemaker Implantation and Clinical Outcomes in Patients With Heart Failure and Preserved Ejection Fraction.
    Shen L; Jhund PS; Docherty KF; Petrie MC; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Swedberg K; Zile MR; McMurray JJV
    JACC Heart Fail; 2019 May; 7(5):418-427. PubMed ID: 30981744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. QRS Duration Is a Predictor of Adverse Outcomes in Heart Failure With Preserved Ejection Fraction.
    Joseph J; Claggett BC; Anand IS; Fleg JL; Huynh T; Desai AS; Solomon SD; O'Meara E; Mckinlay S; Pitt B; Pfeffer MA; Lewis EF
    JACC Heart Fail; 2016 Jun; 4(6):477-86. PubMed ID: 27039126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction.
    Solomon SD; Claggett B; Lewis EF; Desai A; Anand I; Sweitzer NK; O'Meara E; Shah SJ; McKinlay S; Fleg JL; Sopko G; Pitt B; Pfeffer MA;
    Eur Heart J; 2016 Feb; 37(5):455-62. PubMed ID: 26374849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Associations of body mass index with mortality in heart failure with preserved ejection fraction patients with ischemic versus non-ischemic etiology.
    Zeng S; Cai X; Zheng Y; Liu X; Ye M
    Front Cardiovasc Med; 2022; 9():966745. PubMed ID: 35990945
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic importance of left ventricular mechanical dyssynchrony in heart failure with preserved ejection fraction.
    Biering-Sørensen T; Shah SJ; Anand I; Sweitzer N; Claggett B; Liu L; Pitt B; Pfeffer MA; Solomon SD; Shah AM
    Eur J Heart Fail; 2017 Aug; 19(8):1043-1052. PubMed ID: 28322009
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of liver fibrosis risk scores with clinical outcomes in patients with heart failure with preserved ejection fraction: findings from TOPCAT.
    Peters AE; Pandey A; Ayers C; Wegermann K; McGarrah RW; Grodin JL; Abdelmalek MF; Bekfani T; Blumer V; Diehl AM; Moylan CA; Fudim M
    ESC Heart Fail; 2021 Apr; 8(2):842-848. PubMed ID: 33586354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Variation in clinical and patient-reported outcomes among complex heart failure with preserved ejection fraction phenotypes.
    Flint KM; Shah SJ; Lewis EF; Kao DP
    ESC Heart Fail; 2020 Jun; 7(3):811-824. PubMed ID: 32160420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction.
    Minamisawa M; Seidelmann SB; Claggett B; Hegde SM; Shah AM; Desai AS; Lewis EF; Shah SJ; Sweitzer NK; Fang JC; Anand IS; O'Meara E; Rouleau JL; Pitt B; Solomon SD
    JACC Heart Fail; 2019 Aug; 7(8):664-675. PubMed ID: 31302049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perturbations in serum chloride homeostasis in heart failure with preserved ejection fraction: insights from TOPCAT.
    Grodin JL; Testani JM; Pandey A; Sambandam K; Drazner MH; Fang JC; Tang WHW
    Eur J Heart Fail; 2018 Oct; 20(10):1436-1443. PubMed ID: 29893446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Implication of Liver Function Tests in Heart Failure With Preserved Ejection Fraction Without Chronic Hepatic Diseases: Insight From TOPCAT Trial.
    Liang W; He X; Wu D; Xue R; Dong B; Owusu-Agyeman M; Zhao J; Cai L; You Z; Dong Y; Liu C
    Front Cardiovasc Med; 2021; 8():618816. PubMed ID: 34055924
    [No Abstract]   [Full Text] [Related]  

  • 36. Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository Study.
    Myhre PL; Vaduganathan M; O'Meara E; Claggett BL; de Denus S; Jarolim P; Anand IS; Pitt B; Rouleau JL; Solomon SD; Pfeffer MA; Desai AS
    Circ Heart Fail; 2020 Jan; 13(1):e006638. PubMed ID: 31957468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of Sex on Ventricular-Vascular Stiffness and Long-Term Outcomes in Heart Failure With Preserved Ejection Fraction: TOPCAT Trial Substudy.
    Beale AL; Nanayakkara S; Kaye DM
    J Am Heart Assoc; 2019 Jul; 8(13):e012190. PubMed ID: 31230508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
    Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
    Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association Between Metabolic Syndrome and an Increased Risk of Hospitalization for Heart Failure in Population of HFpEF.
    Zhou Y; Fu L; Sun J; Zhu Z; Xing Z; Zhou S; Tai S; Wang Y
    Front Cardiovasc Med; 2021; 8():698117. PubMed ID: 34595217
    [No Abstract]   [Full Text] [Related]  

  • 40. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
    Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
    Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.